S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NYSE:BHVN

Biohaven - BHVN Price Target & Analyst Ratings

$13.68
-0.35 (-2.49%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$13.27
$14.26
50-Day Range
$12.94
$19.20
52-Week Range
$5.54
$20.57
Volume
1.05 million shs
Average Volume
1.00 million shs
Market Capitalization
$933.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.75

Biohaven Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$48.75
256.36% Upside
High Prediction$148.50
Average Prediction$48.75
Low Prediction$21.00
TypeCurrent
3/30/22 to 3/30/23
1 Month Ago
2/28/22 to 2/28/23
3 Months Ago
12/30/21 to 12/30/22
1 Year Ago
3/30/21 to 3/30/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
7 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$48.75$58.32$94.59$151.11
Predicted Upside256.36% Upside16.53% Upside18.12% Upside20.84% Upside
Get Biohaven Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter.

BHVN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BHVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Biohaven Stock vs. The Competition

TypeBiohavenMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.64
2.47
Consensus RatingModerate BuyBuyHold
Predicted Upside247.47% Upside1,935.89% Upside200.53% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/24/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$24.00+25.00%
1/24/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$24.00+25.00%
1/4/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$23.00+70.37%
12/2/2022BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$24.00+45.19%
11/7/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$25.00+61.60%
10/26/2022Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$158.00 ➝ $27.00+87.37%
10/26/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$23.00 ➝ $21.00+45.73%
8/8/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Chico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$148.50+1.03%
5/11/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Douglas Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/6/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight$148.00 ➝ $146.00+19.70%
3/3/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vamil Divan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$144.00 ➝ $154.00+29.66%
1/4/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Esther Rajavelu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$150.00 ➝ $160.00+20.75%
10/6/2021The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$151.00 ➝ $170.00+19.11%
2/5/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
5/8/2020Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Esther Rajavelu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold$41.00-14.12%
(Data available from 3/30/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BHVN Price Target - Frequently Asked Questions

What is Biohaven's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Biohaven stock is Moderate Buy based on the current 3 hold ratings and 6 buy ratings for BHVN. The average twelve-month price prediction for Biohaven is $48.75 with a high price target of $148.50 and a low price target of $21.00. Learn more on BHVN's analyst rating history.

Do Wall Street analysts like Biohaven more than its competitors?

Analysts like Biohaven more than other Medical companies. The consensus rating for Biohaven is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how BHVN compares to other companies.

Does Biohaven's stock price have much upside?

According to analysts, Biohaven's stock has a predicted upside of 14.96% based on their 12-month price targets.

What analysts cover Biohaven?

Biohaven has been rated by JPMorgan Chase & Co., SVB Leerink, and SVB Securities in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:BHVN) was last updated on 3/30/2023 by MarketBeat.com Staff